Akero Therapeutics (AKRO) FY 2025 Conference June 10, 2025 02:40 PM ET Speaker0 Thanks everyone for joining us. I'm Andrew Newkirk, one of the biotech analysts here at Goldman Sachs. I'm really pleased to be joined by Andrew Chang, President and CEO of Akerro. Thanks so much, Andrew. Speaker1 Thanks for having me. Speaker0 Maybe at a high level, let's start with where the NASH field is now. We've obviously seen a lot of development both on the clinical development side with the commercially approved drug la ...

Akero Therapeutics (AKRO) 2025 Conference June 04, 2025 11:45 AM ET Speaker0 All right. Good morning, everyone. Welcome to the next session here at the twenty twenty five Jefferies Healthcare Conference. I am absolutely pleased to have here with us today the CEO of As many of you know, Acero, has had a phenomenal, last couple of years, obviously, with recent, positive, F4 cirrhosis data, amongst other things, and executing on a phase three program. And so, and I might as well just say speculated as a as a p ...

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. Investor Contact: Christina Tartaglia Precision AQ 332.322.7430 Christina.tartaglia@precisionaq.com Media Contact: Peg Rusconi 6 ...

Akero Therapeutics (AKRO) 2025 Conference May 13, 2025 04:40 PM ET Speaker0 And I'm very pleased to have joined me in our first slot of the afternoon session, Andrew Chang, CEO of Vaccaro. Thank you so much for joining us. Speaker1 Thank you for having us, Jason. Well, perfect. Speaker0 Maybe just to start broadly to provide a little context for those newer to the story, Can you describe the role of FGF21 in the pathogenesis of liver fibrosis? Kind of acknowledging that it is somewhat early, but what are so ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. Biotech stocks lagged the broader market in 2023 and 2024, and the SDPR S&P Biotech ETF NYSE: XBI is trading at the same level as in 2017. While biotech stocks soared during the COVID-19 pandemic, investors now view the sector skeptically. Can battered biotech stocks rebound in 2025? While the broader sector may look scary, some companies are making progre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38944 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-5266573 (State or oth ...

Exhibit 99.1 Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025 SYMMETRY study results published in New Engl ...

Core Insights - Akero Therapeutics announced results from the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) [1][6] - The study demonstrated the antifibrotic activity of EFX, with over half of patients treated with 50mg EFX classified as responders by AI-based digital pathology and non-invasive tests, compared to fewer than 5% of placebo patients [2][3] Group 1: Study Details - The HARMONY study was a multicenter, randomized, double-blind, placebo-controlled trial involving 128 biopsy-confirmed adult MASH patients with fibrosis stage 2 or 3 [6] - Patients received either 28 mg or 50 mg EFX or placebo for 24 weeks, with the study continuing for up to 96 weeks [6] - The primary efficacy endpoint was the proportion of subjects experiencing ≥1-stage fibrosis improvement without worsening of MASH [6] Group 2: Results and Analysis - AI-based qFibrosis® analysis showed that after 24 weeks, the antifibrotic effect of EFX was greater than conventional pathology, with 18 patients identified as responders compared to 10 by conventional methods [3] - At Week 96, consistency was observed between conventional pathology and qFibrosis®, with 77% and 81% of patients classified as responders, respectively [3] Group 3: Presentations and Speakers - An oral presentation titled "Alignment of response assessed by non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in metabolic dysfunction associated steatohepatitis (MASH) clinical trials" was given by Prof. Quentin M. Anstee [4] - A poster presentation titled "qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study" was presented by Dr. Jörn M. Schattenberg [5] Group 4: About EFX - Efruxifermin (EFX) is Akero's lead product candidate for MASH, currently evaluated in three ongoing Phase 3 studies [7][8] - EFX has shown potential to reverse fibrosis, resolve MASH, and improve insulin sensitivity and lipoprotein profiles, addressing the complex disease state of MASH [7]

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publication of results from the ...

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the Eur ...